Healthcare Wrap Week 7: Pro Medicus and Cochlear slide as Noxopharm surges on Nature Immunology
11:54am on Saturday 14th of February, 2026 AEDT
Key Points
Pro Medicus (ASX:PME) fell <span class="text-danger"><i class="ci-trending-down me-1"></i>-25.00%</span> even after reporting record half-year results and $280m+ in new contracts
Noxopharm (ASX:NOX) rose <span class="text-success"><i class="ci-trending-up me-1"></i>27.12%</span> after Sofra™ research landed in Nature Immunology
Cochlear (ASX:COH) slid <span class="text-danger"><i class="ci-trending-down me-1"></i>-20.37%</span> as profit fell and the Nexa implant rollout took longer than planned
CSL (ASX:CSL) dropped <span class="text-danger"><i class="ci-trending-down me-1"></i>-16.89%</span> after a large reported profit fall tied to restructuring and impairments